PRESS RELEASE
Active Biotech's Annual Report 2018 is now available for download at www.activebiotech.com.
The Annual Report will only be digitally distributed. The English version will be available within short.
Lund, April 26, 2019
Active Biotech AB (publ)
Helén Tuvesson
CEO
For further information, please contact:
Hans Kolam, CFO
Tel. +46 (0)46 192044
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA (naptumumab), an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11.00 a.m CET on April 26, 2019.
